Bastide Le Confort Médical Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Bastide Le Confort Médical wird ein jährliches Gewinn- und Umsatzwachstum von 30.5% bzw. 5.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 30.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.9% betragen.

Wichtige Informationen

30.5%

Wachstumsrate der Gewinne

30.7%

EPS-Wachstumsrate

Healthcare Gewinnwachstum20.3%
Wachstumsrate der Einnahmen5.4%
Zukünftige Eigenkapitalrendite18.9%
Analystenabdeckung

Low

Zuletzt aktualisiert05 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Like These Underlying Return On Capital Trends At Bastide Le Confort Médical (EPA:BLC)

Jun 14
We Like These Underlying Return On Capital Trends At Bastide Le Confort Médical (EPA:BLC)

Bastide Le Confort Médical (EPA:BLC) Has A Somewhat Strained Balance Sheet

May 27
Bastide Le Confort Médical (EPA:BLC) Has A Somewhat Strained Balance Sheet

Why Investors Shouldn't Be Surprised By Bastide Le Confort Médical SA's (EPA:BLC) 28% Share Price Surge

May 12
Why Investors Shouldn't Be Surprised By Bastide Le Confort Médical SA's (EPA:BLC) 28% Share Price Surge

Is Now An Opportune Moment To Examine Bastide Le Confort Médical SA (EPA:BLC)?

Apr 27
Is Now An Opportune Moment To Examine Bastide Le Confort Médical SA (EPA:BLC)?

Investors Can Find Comfort In Bastide Le Confort Médical's (EPA:BLC) Earnings Quality

Apr 06
Investors Can Find Comfort In Bastide Le Confort Médical's (EPA:BLC) Earnings Quality

Benign Growth For Bastide Le Confort Médical SA (EPA:BLC) Underpins Stock's 26% Plummet

Mar 28
Benign Growth For Bastide Le Confort Médical SA (EPA:BLC) Underpins Stock's 26% Plummet

Positive Sentiment Still Eludes Bastide Le Confort Médical SA (EPA:BLC) Following 28% Share Price Slump

Feb 08
Positive Sentiment Still Eludes Bastide Le Confort Médical SA (EPA:BLC) Following 28% Share Price Slump

The Return Trends At Bastide Le Confort Médical (EPA:BLC) Look Promising

Nov 18
The Return Trends At Bastide Le Confort Médical (EPA:BLC) Look Promising

What Is Bastide Le Confort Médical SA's (EPA:BLC) Share Price Doing?

May 17
What Is Bastide Le Confort Médical SA's (EPA:BLC) Share Price Doing?

Bastide Le Confort Médical (EPA:BLC) Is Doing The Right Things To Multiply Its Share Price

Jan 27
Bastide Le Confort Médical (EPA:BLC) Is Doing The Right Things To Multiply Its Share Price

Is Bastide Le Confort Médical SA (EPA:BLC) Potentially Undervalued?

Nov 22
Is Bastide Le Confort Médical SA (EPA:BLC) Potentially Undervalued?

Bastide Le Confort Médical (EPA:BLC) Is Reinvesting At Lower Rates Of Return

Sep 21
Bastide Le Confort Médical (EPA:BLC) Is Reinvesting At Lower Rates Of Return

Is It Time To Consider Buying Bastide Le Confort Médical SA (EPA:BLC)?

Jul 28
Is It Time To Consider Buying Bastide Le Confort Médical SA (EPA:BLC)?

When Should You Buy Bastide Le Confort Médical SA (EPA:BLC)?

Mar 18
When Should You Buy Bastide Le Confort Médical SA (EPA:BLC)?

Be Wary Of Bastide Le Confort Médical (EPA:BLC) And Its Returns On Capital

May 16
Be Wary Of Bastide Le Confort Médical (EPA:BLC) And Its Returns On Capital

Here's Why Bastide Le Confort Médical (EPA:BLC) Has A Meaningful Debt Burden

Apr 30
Here's Why Bastide Le Confort Médical (EPA:BLC) Has A Meaningful Debt Burden

We Think Bastide Le Confort Médical's (EPA:BLC) Profit Is Only A Baseline For What They Can Achieve

Apr 07
We Think Bastide Le Confort Médical's (EPA:BLC) Profit Is Only A Baseline For What They Can Achieve

Should You Think About Buying Bastide Le Confort Médical SA (EPA:BLC) Now?

Mar 10
Should You Think About Buying Bastide Le Confort Médical SA (EPA:BLC) Now?

Is Bastide Le Confort Médical SA's (EPA:BLC) 16% ROE Better Than Average?

Feb 21
Is Bastide Le Confort Médical SA's (EPA:BLC) 16% ROE Better Than Average?

Bastide Le Confort Médical SA's (EPA:BLC) Intrinsic Value Is Potentially 33% Above Its Share Price

Feb 07
Bastide Le Confort Médical SA's (EPA:BLC) Intrinsic Value Is Potentially 33% Above Its Share Price

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:BLC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/20276262530941
6/30/20265962632933
6/30/20255602227863
6/30/20245281626783
12/31/202352363488N/A
9/30/2023516114397N/A
6/30/20235081652106N/A
12/31/2022495181568N/A
9/30/202248216963N/A
6/30/202246814457N/A
12/31/2021446133381N/A
9/30/2021445133178N/A
6/30/2021444132874N/A
3/31/2021436121965N/A
12/31/2020428111155N/A
9/30/202040511951N/A
6/30/202038312847N/A
3/31/202036591655N/A
12/31/201934772562N/A
9/30/201934162662N/A
6/30/201933662761N/A
3/31/201932872258N/A
12/31/201832191856N/A
9/30/201830581553N/A
6/30/201828971250N/A
3/31/20182676743N/A
12/31/20172455135N/A
9/30/20172325N/A31N/A
6/30/20172185N/A26N/A
3/31/20172116N/A26N/A
12/31/20162037N/A25N/A
9/30/20161987N/A28N/A
6/30/20161927N/A32N/A
3/31/20161877N/A32N/A
12/31/20151827N/A32N/A
9/30/20151777N/A28N/A
6/30/20151717N/A24N/A
3/31/20151667N/AN/AN/A
12/31/20141606N/A19N/A
9/30/20141566N/A19N/A
6/30/20141525N/A18N/A
3/31/20141485N/AN/AN/A
12/31/20131435N/A19N/A
9/30/20131394N/A19N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BLCDas prognostizierte Gewinnwachstum (40.3% pro Jahr) liegt über der Sparquote (1.1%).

Ertrag vs. Markt: BLCDie Erträge des Unternehmens (40.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (11% pro Jahr).

Hohe Wachstumserträge: BLCEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: BLCDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.8% pro Jahr).

Hohe Wachstumseinnahmen: BLCDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BLCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.9%).


Wachstumsunternehmen entdecken